Previous close | 4.1500 |
Open | 4.1800 |
Bid | 3.9800 x 200 |
Ask | 4.0200 x 200 |
Day's range | 3.9900 - 4.1900 |
52-week range | 2.0100 - 6.1300 |
Volume | |
Avg. volume | 976,625 |
Market cap | 327.995M |
Beta (5Y monthly) | 1.09 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.8800 |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 12.30 |
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient expansion phase well underway in Phase 2 study of luvelta in combination with bevacizumab; enrollment is expected to complete in the first half of 2024 - - The randomized portion of REFRαME-O1, the registration-enabling study of luvelta for patients with platinum-resistant ovarian cancer, is
Sutro Biopharma (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Every investor on earth makes bad calls sometimes. But you want to avoid the really big losses like the plague. So...